Clinical Trial Update: T-Cell Turnover Following Vaccination With MVA85A [Phase 1]

View source ↗

Summary

A Phase 1 trial in tuberculosis examined T-cell turnover after vaccination with MVA85A. The study is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA85A (Modified Vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED